Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER1202
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 12 Aug 2021 Results assessing cost-effectiveness analysis of anlotinib as third- or further-line of treatment in patients with relapsed advanced small cell lung cancer in China, published in the Advances in Therapy.
    • 18 May 2021 Results evaluating the efficacy and safety of anlotinib as a third-line and subsequent treatment for patients with small cell lung cancer, published in the British Journal of Cancer
    • 21 Sep 2020 Results of a comparative analysis for patients with pleural metastases/pleural effusion in a subgroup of patients, presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top